Literature DB >> 20804474

Bleeding after holmium laser enucleation of the prostate: lessons learned the hard way.

Aaron D Martin1, Rafael N Nunez, Mitchell R Humphreys.   

Abstract

OBJECTIVE: To examine specific causes of postoperative bleeding requiring transfusion after holmium laser enucleation of the prostate (HoLEP) in order to enhance preoperative screening and counseling.
MATERIALS AND METHODS: After Institutional Review Board (IRB) approval, a retrospective review of a single surgeon's experience of 130 consecutive HoLEPs was performed to specifically examine patients requiring perioperative blood transfusions. All patients from August 2007 to April 2009 who underwent a HoLEP at our institution since its inception were included. These patients' charts were reviewed to gain insight into their bleeding diathesis. A case series report was compiled and compared with the relevant published literature.
RESULTS: Of the 130 patients, eight (6.7%) were found to require transfusion postoperatively. Four of these patients required a second operation for completion. These patients had a variety of causes for increased bleeding and subsequent transfusion including: chronic anticoagulation (n = 1), significant cardiac disease requiring maintenance of hemoglobin (n = 4), sepsis with secondary disseminated intravascular coagulation (n = 1), large prostate size (>150 g) (n = 4), underlying prostate cancer (n = 1) and inadequate anesthesia during the procedure leading to patient movement (n = 1). All patients made a full recovery with satisfactory urinary symptom improvement except for one patient with residual incontinence at last follow-up.
CONCLUSIONS: Despite the many benefits of holmium laser enucleation, all patients should be counseled regarding the real potential for postoperative blood transfusion. When feasible, any known bleeding risk should be minimized by the surgeon as long it is done safely for the benefit of the patient considering their co-morbidities.
© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2010        PMID: 20804474     DOI: 10.1111/j.1464-410X.2010.09560.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy.

Authors:  Christopher Netsch; M Stoehrer; M Brüning; A Gabuev; T Bach; T R W Herrmann; A J Gross
Journal:  World J Urol       Date:  2013-05-09       Impact factor: 4.226

2.  Transurethral surgical anatomy of the arterial bleeder in the enucleated capsular plane of enlarged prostates during holmium laser enucleation of the prostate.

Authors:  Min Soo Choo; Hahn-Ey Lee; Jungbum Bae; Sung Yong Cho; Seung-June Oh
Journal:  Int Neurourol J       Date:  2014-09-24       Impact factor: 2.835

3.  Efficacy and safety of 120-W thulium:yttrium-aluminum-garnet vapoenucleation of prostates compared with holmium laser enucleation of prostates for benign prostatic hyperplasia.

Authors:  Kai Hong; Yu-Qing Liu; Jian Lu; Chun-Lei Xiao; Yi Huang; Lu-Lin Ma
Journal:  Chin Med J (Engl)       Date:  2015-04-05       Impact factor: 2.628

Review 4.  Comparative efficacy and safety of holmium laser enucleation of the prostate (HoLEP) using moses technology and standard HoLEP: A systematic review, meta-analysis, and meta-regression.

Authors:  Muhammad Zaniar Ramadhani; Yudhistira Pradnyan Kloping; Ilham Akbar Rahman; Niwanda Yogiswara; Johan Renaldo; Soetojo Wirjopranoto
Journal:  Ann Med Surg (Lond)       Date:  2022-08-12

5.  Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction.

Authors:  Nikesh Thiruchelvam
Journal:  Indian J Urol       Date:  2014-04

6.  Predictive risk factors of postoperative urinary incontinence following holmium laser enucleation of the prostate during the initial learning period.

Authors:  Shuichiro Kobayashi; Masataka Yano; Takayuki Nakayama; Satoshi Kitahara
Journal:  Int Braz J Urol       Date:  2016 Jul-Aug       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.